Acrodermatitis continua of Hallopeau (ACH) is a rare manifestation of pustular psoriasis which may considerably disable affected patients. In this case report we confirm the efficacy of acitretin in the treatment of ACH and, in addition, describe the course of the myelodysplastic syndrome (MDS) from which the patient was suffering. During acitretin treatment, there was a transformation into acute myeloid leukaemia. We discuss the effect of retinoids on the bone marrow of normal subjects, patients with AIDS, and patients with acute myeloid leukaemia.
Acrodermatitis continua of Hallopeau (ACH) is a rare type of localized pustular psoriasis. The condition is characterized by the occurrence of pustules on the fingers and toes. Systemic antipsoriatic treatments are indicated in ACH. Although no controlled studies are available, ACH is reported to respond well to systemic cortico-1_Q steroids, methotrexate, acitretin, and cyclosporin.
Recently, we have treated a patient with ACH, who also had a myelodysplastic syndrome (MDS) with a refractory anaemia (RA) and a severe thrombocyto penia. The severity of the ACH necessitated systemic treatment, and the patient was given acitretin with careful monitoring of the blood parameters.
Case report
In 1989, a 53-year-old m an presented with an erythematosquamous and pustular eruption of the toes. Haematological investigation showed severe thrombo cytopenia (platelet count 5-20 x 199/1), and a bone marrow examination was hypercellular, with myelodisplasia, and a low number of megakaryocytes. The disorder was classified as MDS, RA-type since there were normal blast counts. HLA typing revealed: -A3, -A28, B27, -B35, -CW1, and -CW4. Treatment was started w ith methylprednisolone, 50 mg/day. Although the skin condition showed some improvement with this thrombocytopenia ß mg/day and-propranolol, 40 mg three times because of a supraventricular tachycardia, and he took omeprazole for gastrointestinal discomfort and bleeding.
ACH, w ith chronic plaque psoriasis, was diagnosed, and the patient was treated with low-dose methotrex ate, firstly at a dose of 5 mg/week and, later, 10 mg/ week. Methylprednisolone was continued, at a dosage of 2 5 mg/day and, in addition, the patient used potent topical corticosteroids.
Episodes of epistaxis, purpura, and gastrointestinal bleeding required frequent transfusions of blood and platelets. Cytogenetic investigations showed trisomy 10, which confirmed the diagnosis of MDS. Methotrex ate, methylprednisolone and propranolol were stopped. Treatment was started with interleukin (IL)-3, at a dosage of 10/ig/kg per day. According to the EORTC protocol for MDS, IL-3 was stopped, after 3 weeks, because of fever, loss of appetite, and general malaise. During this treatment, the patient's skin condition got worse and required additional treatment.
Examination showed well-demarcated, erythematosquamous lesions, covered with yellow crusts, on three fingers of the right hand, and on all 10 toes (Fig. 1) . A paronychia and distal onycholysis of the first finger of the left hand, was present. On the soles, scalp and neck, there were well-demarcated erythematosquamous pla ques, with a psoriasiform appearance. In the intergluteal area, a well-demarcated erythema was seen. On the buttocks and upper legs there was purpura. Cultures for fungi were negative. In January 1992, acitretin (Neotigason; Hoffman LaRoche) was started, at a dosage of 35 mg/day (the patient weighed 84 kg). Topical treatment with corti costeroids and tar preparations was continued. After 2 weeks of treatment, a substantial improvement was seen (Fig. 2) . Subsequently, the dosage of acitretin w as increased to 40mg/day, and there was a m ild cheilitis, indicating that the dosage was sufficient. D uring subsequent months, the skin condition improved further, to the extent that only m inim al residual changes persisted. During the 7 months of treatm ent with acitretin, at a dosage of 3 5-40 mg/ day, no side-effects, apart from m ild cheilitis, were recorded. The serum cholesterol, triglycerides, and transaminases remained within the norm al range. No j oint complaints were recorded.
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However, during this period, clinically evident bleed ing from the gastrointestinal tract necessitated platelet transfusions. The frequency of these transfusions was comparable to that in the period before treatment w ith acitretin. The platelet counts remained in the same range as before treatment w ith acitretin, i.e. 5-40 x 10 /1. In February 1992, anaemia developed, and a gradual increase in the leucocyte and blast counts was seen. In May 1992, whilst the patient was still on treatment with acitretin, acute myeloid After the first course, complete remission was not obtained and a pancytopenia persisted. During the second remission-induction course, the patient died, after 5 weeks, due to cerebral bleeding.
Discussion
Although there are no placebo-controlled studies for acitretin in ACH, the use of acitretin in localized and generalized pustular psoriasis is well established. So far, there are only two case reports on the treatment of ACH.2,9 Our report confirms the efficacy of acitretin in this rare condition. The decision to initiate treatment with acitretin was justified by the severe and disabling symptoms, but was complicated by the coexistence of MDS, which necessitated intensive haematological supervision. The published literature is not clear as to whether treatment with systemic retinoids is allowed or contraindicated in patients with MDS. Studies in the 1920s reported a reduction of haematopoietic cells in the bone marrow of vitamin A-depleted animals. In hum an vitamin A deficiency, moderate anaemia develops despite ample dietary sources of all essential nutrients except the vitamin A. Etretinate, the ester of 10, 11 acitretin (at 10 to 10-/ mol/1) has been reported to increase the clone size of colony-forming unitgranulocyte macrophage (CFU-GM) from normal human bone marrow, in contrast to the inhibitory effect of 13-cis-retinoic acid. 13 The effects of retinoids on the normal bone marrow are not well understood.
Several reports in the literature indicate that retinoids have a beneficial effect on the course of MDS. Clark et al. reported a significant increase in the 1-year survival, from 30 to 77%, in the treated group in non-sideroblastic patients, and no significant effect in patients with sideroblastic anaem ia.14 Koeffler et al. did not find a significant response in patients with MDS. 7 
IS
the patients in this group had either high-risk disease or sideroblastic anaemia. In these, the result of Clark et a l also indicate no significant improvement. 15 In cultures from patients with MDS, 20 of 34 cases showed greater inhibition of total colony numbers than controls, and some patients proved to have greater sensitivity than normal subjects with respect to the inhibitory effect of retinoic acid.15 In short-term liquid cultures of bone marrow from 13 patients with MDS, 13-cis-retinoic acid induced a significant decrease in the number of pro myelocytes and Leu-M3 positive cells. Hence, retinoids seem to induce a shift from monocytoid to myeloid differentiation. However, etretinate in culture did not show any capacity to induce differentiation. 30 The role of acitretin and its ester, etretinate, in the develop ment of promyelocytic cell lines and leukaemia is less clear. Several authors report etretinate to be unable to induce 31 -3 3 ation in U-937 and 111,-60 cell lack of efficacy, in contrast to effect of iill-trans retinoic acid, was shown in the case of acute promyelocytic leukaemia. 1 Conversely, some reports suggest that retinoids might have an unfavour able effect on the course of leukaemia. Lawrence et al. 55 noted that, in some patients with acute myeloblastic leukaemia, clonal growth of CFU-GM in vitro was stimulated sometimes by retinoic acid, and that in vivo the effect may vary from patient to patient. Awareness of the deleterious effect of retinoid therapy is important in patients who have the more malignant variants of MDS. Garewal 
